AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00554346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arcoxia(etoricoxib 90 mg/tablet)
Description: Arcoxia(etoricoxib 90 mg/tablet) or placebo, #1, 3 days
Study NCT00554346 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Arcoxia(etoricoxib 90 mg/tablet)
Description: Arcoxia(etoricoxib 90 mg/tablet) or placebo, #1, 3 days
Study NCT01979328 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: geko
Study NCT01979328 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plaster cast
Study NCT00698139 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic Pacemaker
Description: Patients will come to clinic in the morning for baseline measurements. Subsequently, the atrial pacing rate will be increased to 85bpm for 6 hours. The control group will be given the illusion that their pacer has been adjusted, but the settings will remain unchanged. Patients will eat a standard breakfast provided by the hospital prior to the treatment session, and then will fast for the six-hour observation period. Patients will remain in supine position and will be clinically monitored for 6 hours. All patients will be on continuous cardiac monitors. Vital signs and symptoms of congestion/ischemia will be recorded every hour.
Study NCT03185169 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Replens and coconut oil
Study NCT03670693 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dual-energy X-ray absorptiometry (DEXA scan)
Description: Body composition will be assessed via DEXA scan (Lunar Prodigy, GE Medical Systems, Bucks, UK)
Study NCT04366128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAPA indution immunotherapy
Description: 1. Camelirumab 200mg Intravenous injection on day 1.~2. Apatinib 250mg taken orally once daily.~3. Pegaspargase 2000U/m2 Intramuscular injection on day 1.
Study NCT01962116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citrate 4%
Study NCT01962116 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: unfractionated heparin
Study NCT02916628 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: group counseling
Description: Group counseling with positive psychology and motivational interviewing was undertaken once per week for 6 weeks.
Study NCT02916628 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: group counseling
Description: Group counseling with positive psychology and motivational interviewing was undertaken once per week for 6 weeks.
Study NCT02916628 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auricular acupressure
Description: Auricular acupressure using acupellets was performed for 6 weeks continuously
Study NCT02916628 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo acupressure
Description: Placebo acupellets were prepared without metal projections, and placed on both sides in the same areas of the ear as the active condition.
Study NCT01080625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenylephrine
Description: 100 mcg of phenylephrine (volume 10 ml) iv at the time of reperfusion
Study NCT02021240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Study NCT02021240 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Study NCT01080625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epinephrine
Description: 10mcg of epinephrine (volume 10 ml) is administered iv at the time of reperfusion
Study NCT01080625 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo control
Description: 10ml of normal saline is administered at the time of reperfusion
Study NCT03670693 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Supine cardiorespiratory fitness assessment
Description: VO2 peak will be quantified during completion of a continuous, incremental exercise test performed in the supine position on an MR adapted stepper machine (Ergospect, Innsbruck Austria)
Study NCT03670693 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: fMRI Exercise assessment
Description: Measurement of cardiac output and, cerebral and regional perfusion using Blood-Oxygen-level-dependent (BOLD) measures and arterial spin-labelling (ASL)-MRI as well as fractional oxygen extraction using TRUST-MRI during supine exercise of the quadriceps with the MR compatible cardiostepper (Ergospect, Innsbruck, Austria) at 50% of relative VO2 peak as measured during the supine cardiorespiratory fitness assessment.
Study NCT03022604 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: C4/Generation 4
Description: 12 grams of C4/Generation 4
Study NCT03022604 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: C450X
Description: 12 grams of C450X
Study NCT03022604 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 12 grams of flavored dextrose
Study NCT03249441 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassion-focused therapy
Description: Session-by-session summary of CFT:~Week 1: Understanding your relationship with food Week 2: Making sense of overeating Week 3: The Compassionate Mind/ Preparing your mind for compassion Week 4: Developing the skill of self-compassion Week 5: Why we overeat - a Compassionate approach Week 6: Understanding your current eating pattern Week 7: Motivating yourself to change Week 8: Determining what your body needs Week 9: Towards a new way of eating Week 10: Compassionate letter writing and developing a compassionate focus on eating.~__________________________________________________________________________
Study NCT01045551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: 20mg taken orally twice per day for 12 weeks
Study NCT02676050 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optical Imaging Agents (EMI-137, NAP)
Description: Both optical imaging agents (NAP and EMI-137) will be administered to each patient during a bronchoscopy procedure. A novel delivery catheter (to deliver both agents), imaging fibre and endomicroscopy system with viewer software will be used to detect c-MET and activated neutrophil signal in the human lung.
Study NCT02676050 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delivery Device Cathetar and Miniaturised imaging fibre
Description: Both optical imaging agents (NAP and EMI-137) will be administered and imaged simultaneously during a bronchoscopy procedure using the devices mentioned above.
Study NCT02676050 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical endomicroscopy system
Description: The signal emitted by both optical imaging agents (NAP and EMI-137) will be visualised using a novel endomicroscopy system.
Study NCT01701349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosbretabulin + paclitaxel + carboplatin
Description: Fosbretabulin 200 mg/m2 IV infusion
Study NCT01701349 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + paclitaxel + carboplatin
Description: Paclitaxel 200 mg/m2, Carboplatin AUC 6 IV infusion
Study NCT02300844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0174-0833
Description: Subjects will receive a single s.c. (subcutaneous/under the skin) dose of NNC0174-0833.~Up to nine dose levels of single s.c. doses of NNC0174-0833 are planned to be investigated.
Study NCT02300844 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects will receive a single s.c. (subcutaneousl/under the skin) dose.
Study NCT00372294 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pyrimethamine-sulfadiazine + prednisolone
Description: Administration of pyrimethamine-sulfadiazine + prednisolone
Study NCT00372294 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin+Dexamethasone
Description: Intravitreal injection of Clindamycin+Dexamethasone
Study NCT01565460 — intervention group
Intervention type: OTHER
Intervention: Sample Collection
Description: Sample Collection: bile and pancreatic duct brushings and fluid samples will be obtained from the pancreatic stricture during endoscopic retrograde cholangiopancreatic procedure.
Study NCT00307892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Traumeel S: intra-operative irrigation + oral ingestion
Description: homeopathic remedy
Study NCT00307892 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo remedy
Study NCT03419351 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Smartphone
Description: Smartphone based measurement of refractive error and visual acuity testing using these measurements.
Study NCT03419351 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Autorefractor
Description: Autorefractor based measurement of refractive error and visual acuity testing using these measurements.
Study NCT03419351 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Individual
Description: Individual, human measurement of refractive error and visual acuity testing using these measurements.
Study NCT04460300 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aromatherapy-inhalation method
Description: In addition to the pharmacological treatment prescribed by the physician to individuals in this group, aromatherapy is carried out through the essential oil inhalation method. Individuals who can distinguish odors in the odor sense test before the application is included in the study. Aromatherapy inhalation is applied for three days and every other day (eg Monday-Wednesday-Friday) determined by the researchers for a week. Intervention is made between 07:00 and 08:00 in the morning hours when the blood cortisol value is maximized and homogeneity is provided.~In this method, 5 drops of lavender oil will be dropped directly on a sterile gauze and individuals will be allowed to breathe from a distance of 10 cm for 5 minutes.
Study NCT04460300 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aromatherapy-foot massage group
Description: In addition to the pharmacological treatment prescribed by the physician to individuals in this group, aromatherapy is applied through foot massage. Swedish massage protocol is followed in foot massage intervention.The foot massage is performed on three days and every other day (eg Monday-Wednesday-Friday) determined by the researchers for a week.The intervention is performed between 07:00 and 08:00 in the morning hours when the blood cortisol value is maximized and homogeneity is provided.~Foot massage is done with 10 drops (5 drops per foot) of lavender for 10 minutes for each foot for 20 minutes. During the intervention, 20 techniques is used and the application time of each technique is 30 seconds (total 10 minutes per foot).
Study NCT01449344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab 375mg/m² IV , day 1
Study NCT01449344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375mg/m² IV , day 1
Study NCT01449344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High dose Ara-C
Description: Ara-C 2000 mg/m² (patients >65 years or s/p myeloablative treatment: 1000 mg/m²) IV, d 2 and 3
Study NCT01449344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose Ara-C
Description: Ara-C 2000 mg/m² (patients >65 years or s/p myeloablative treatment: 1000 mg/m²) IV, d 2 and 3
Study NCT01449344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 40 mg PO, day 1-4
Study NCT01449344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40 mg PO, day 1-4
Study NCT01449344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib 1.5 mg/m² IV, day 1 and 4
Study NCT03006367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NFC-1 100 mg
Study NCT03006367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NFC-1 200 mg
Study NCT03006367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NFC-1 400 mg
Study NCT01984359 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Obtaining Human tissue
Study NCT03990324 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual stretching
Description: Manual stretching for the upper trapezius and levator scapulae muscle
Study NCT02432690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI503
Description: BBI503 will be administered orally, once daily. Dosing will begin at 200 mg once daily, preferably at bedtime and 2 hours after a meal. Dose modification in case of adverse events is allowed according to the schedule below; Full dose: 200 mg daily, Modification Level-1: 100 mg daily, Modification Level-2: 50 mg daily.
Study NCT04892394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information Types Before Endodontic Treatment
Description: The first aim of this study is to compare the effect of detailed video information or basic verbal information on the anxiety levels of patients by using anxiety scales before treatment. The second aim is to evaluate the effect of pretreatment video or verbal information on the stress level occurring in patients during the endodontic treatment steps by using electrodermal activity. The third aim is to investigate the relationship between patients' pretreatment anxiety levels and socio-demographic characteristics which are thought to play a role in anxiety's etiology.
Study NCT03832166 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fruits and Vegetables
Description: Fruits and vegetables delivery, once/week for 24 weeks
Study NCT03832166 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cooking
Description: Nutrition education and cooking instruction class, one class/week for 6 weeks
Study NCT00510575 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal rod
Description: Posterior spinal fusion using a 5.5 or 6.35 size rod
Study NCT03289494 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balanced diet high in Slowly Digestible Starch
Description: The carbohydrate present in the diet high in Slowly Digestible Starch were selected according to the general recommendations made for diabetics and according to their SDS content. The diet will be consumed during one week.
Study NCT03289494 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Balanced diet low in Slowly Digestible Starch
Description: The carbohydrate present in the diet low in Slowly Digestible Starch were selected according to the general recommendations made for diabetics and according to their SDS content. The diet will be consumed during one week.
Study NCT00896350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Care Chemoradiation
Description: External beam radiation to the neck and tumor site of head and neck. Concurrent platinum based chemotherapy. External beam boost at discretion of treating physician.
Study NCT01652222 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CONEM-BETA + socio-educational training
Description: 4 socio-educative training sessions during 8 weeks, and caregivers will systematically play with their patients with CONEM-BETA therapeutic game during the last 4 weeks. The dyads will be assessed (primary timepoint). Caregivers will then continue using the game with their patients for an extra 6 weeks period as needed, to assess adherence and games preferences.
Study NCT01652222 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Socio-educational training only
Description: 4 socio-educative training sessions during 8 weeks
Study NCT02336880 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioural therapy
Study NCT03327246 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connecare self managment system
Description: The CONNECARE SMS will rely on a hybrid solution that, besides being autonomous (the patient may use the SMS to monitor and access to her/his data and information), has also a collaborative component (through the interaction with the SACM) to allow participation by clinicians and to provide feedback to them. In so doing, the patient may control her/his activity, receiving recommendations to improve the treatment and to be encouraged in following it.
Study NCT00741767 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: salmeterol-fluticasone
Description: 250ug salmeterol/50ug fluticasone inhaled via an oral inhaler twice daily
Study NCT01440972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: partial blood flow restriction (PBFR)
Description: low intensity resistance training with partial blood flow restriction 3 times/week for 4 weeks.
Study NCT01440972 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low intensity resistance training
Description: low intensity resistance training without partial blood flow restriction
Study NCT04447625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral antibiotic administration
Description: per os antibiotic administration as the standard line of strategy for treating CE of doxycycline at a dosage of 100mg twice a day for 14 days and metronidazole of 500mg twice a day for 14 days
Study NCT04447625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral antibiotic administration
Description: per os antibiotic administration as the standard line of strategy for treating CE of doxycycline at a dosage of 100mg twice a day for 14 days and metronidazole of 500mg twice a day for 14 days
Study NCT04447625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrauterine antibiotic infusion
Description: intrauterine infusion of 3ml of ciprofloxacin at a concentration of 200 mg/100 ml
Study NCT00068822 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty
Description: Placement of polymethylmethacrylate (PMMA) into vertebral compression fracture
Study NCT00068822 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham vertebroplasty
Description: Participants, following local anesthesia with lidocaine and bupivacaine, were given verbal and physical cues such as pressure on the back, but the needle was not placed.
Study NCT01495689 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ottawa Model with SmartCard
Description: On-site counseling for Smoking Cessation along with the IVR automated telephone call follow-up and SmartCard worth $110 towards purchase of smoking cessation aids
Study NCT01495689 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care or control arm will receive strong physician advice, brief counseling from clinic nurse +/- a prescription for smoking cessation aid if requested and willing
Study NCT04409990 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Shear Wave Elastography
Description: SWE value of rectal lesions
Study NCT01804647 — intervention group
Intervention type: OTHER
Intervention: No study treatments administered - blood draws only
Study NCT03783013 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: High Lycopene Tomato Juice With Soy Germ Extract
Description: Tomato juice made from high lycopene tomatoes with soy germ extract added
Study NCT03783013 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Low Lycopene Tomato Juice
Description: Tomato juice made from low lycopene tomatoes with no soy germ extract added
Study NCT02147106 — intervention group
Intervention type: OTHER
Intervention: Videoconsultation
Study NCT00678249 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLAIR Endovascular Stent Graft
Description: Primary balloon angioplasty followed by placement of the FLAIR Endovascular Stent Graft
Study NCT00678249 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PTA
Description: Percutaneous Transluminal Angioplasty
Study NCT00678249 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLAIR Endovascular Stent Graft
Description: Primary PTA followed by placement of the FLAIR Endovascular Stent Graft. Roll-in participants were enrolled in the study for training purposes and were not randomized.
Study NCT01166386 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FANCI
Description: comprehensive neurobehavioral sessions with therapist administrating treatment components
Study NCT03670693 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Muscle deconditioning assessment
Description: Limb blood flow will be occluded with a cuff, whilst participants perform repeated plantar flexion exercise in a MRI scanner. This will drive PCr, (the available reserve of ATP) to zero. Once the cuff is removed, they will undergo non-invasive and well-established in vivo 31P magnetic resonance (31P MRS) measurements on the gastrocnemius to determine PCr re-synthesis rate during resting recovery.
Study NCT01166386 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: FANCI
Description: Watching DVDs chosen by participants on various topics.
Study NCT01961128 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Study NCT00708773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 90 minute IV infusion once every 3 weeks.~Dose will be based on sex and genotype determination.
Study NCT03792763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
Description: Administration every 4 weeks (Q4W) for 6 months then every 3 months (Q3M) for a total of 3 years or until progression to active, symptomatic MM